ContraFect Corp. | Key People and Executives
Steven C. Gilman
Executive Chairman, President & CEO
Cary William Sucoff
Independent Director
Sol J. Barer
Lead Independent Director
David N. Low
Independent Director
Isaac Blech
Independent Director
Roger J. Pomerantz
Vice Chairman
Michael J. Otto
Independent Director
Steven C. Gilman
Executive Chairman, President & CEO
Michael Messinger
Principal Financial Officer & Senior VP-Finance
Cara Cassino
Chief Medical Officer & EVP-Research & Development
Nancy Dong
Vice President-Finance & Administration
Raymond Schuch
Vice President-Research
Paul Boni
Investor Relations Contact
Bogdanos Natalie
Secretary & General Counsel
Cary William Sucoff
Independent Director
Sol J. Barer
Lead Independent Director
David N. Low
Independent Director
Isaac Blech
Independent Director
Roger J. Pomerantz
Vice Chairman
Michael J. Otto
Independent Director
| Address |
28 Wells Avenue
Yonkers New York 10701
United States
|
|
Employees
|
- |
| Website |
http://www.contrafect.com |
| Updated |
07/08/2019 |
| ContraFect Corp. engages in discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases. Its pipeline consists of CF-301, a bacteriophage-derived lysin with potent activity against Staphylococcus aureus bloodstream infections; and CF-404, which composed of three fully human monoclonal antibodies designed to treat all seasonal strains of human influenza. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY. |
